文献速递核素与放射性配体治疗肿瘤 PET/CT

改进的211At标记PSMA靶向α治疗药物

An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy.
PubMed 文献 · J Nucl Med · 2021-06-04

研究合成并筛选出新型211At标记PSMA靶向化合物211At-3-Lu,在细胞和动物模型中评估其摄取、生物分布及疗效。结果显示该化合物在PSMA阳性肿瘤中摄取高,肿瘤与唾液腺及肾脏比值高,脱砹不显著,高剂量下呈剂量依赖性生存获益,且长期毒性研究显示脱靶毒性小。结论认为211At-3-Lu或类似物可能在前列腺癌治疗中提供有限且可接受的毒性并保持疗效。

要点

  • 211At-3-Lu在PSMA阳性PC3 PIP肿瘤1小时摄取达30.6±4.8 %ID/g,24小时降至9.46±0.96 %ID/g。
  • 肿瘤与唾液腺及肾脏比值分别为4小时129±99、24小时130±113。
  • 高剂量(>1.48 MBq)下在侧腹和转移模型中显示剂量依赖性生存获益,脱靶毒性小。

核心结论

  • 化合物211At-3-Lu或相近类似物可能在前列腺癌治疗中提供有限且可接受的毒性,同时保持疗效。

研究设计与样本

  • 合成一系列125I标记化合物以评估放射性卤素位置和螯合物中镥对生物分布的影响,据此选定211At-3-Lu。
  • 在细胞摄取和内化研究中评估211At-3-Lu,并在实验性侧腹和转移(PC3-ML-Luc)模型中评估生物分布及PSMA表达(PSMA+)PC3 PIP肿瘤生长控制。
  • 对211At-3-Lu进行为期13个月的长期毒性研究,包括组织化学和病理学检查。

主要发现

  • 211At-3-Lu的放射化学产率为17.8%±8.2%。
  • 孵育4小时后,211At-3-Lu在PSMA+ PC3 PIP细胞中的总摄取为输入剂量的13.4±0.5%,对照细胞摄取很少。
  • 在SCID小鼠中,注射后1小时PSMA+ PC3 PIP肿瘤摄取为30.6±4.8 %ID/g,24小时降至9.46±0.96 %ID/g。
  • 肿瘤与唾液腺及肾脏比值分别为4小时129±99和24小时130±113。
  • 脱砹不显著(4小时胃0.34±0.20 %ID/g)。

临床怎么用

  • 211At-3-Lu或相近类似物可能用于PSMA阳性前列腺癌的α治疗,需关注剂量依赖性疗效及长期毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved effective in treating patients with prostate cancer who were unresponsive to the corresponding β-particle therapy. 211At is an α-emitter that may engender less toxicity than other α-emitting agents. We synthesized a new 211At-labeled radiotracer targeting PSMA that resulted from the search for a pharmacokinetically optimized agent. Methods: A small series of 125I-labeled compounds was synthesized from tin precursors to evaluate the effect of the location of the radiohalogen within the molecule and the presence of lutetium in the chelate on biodistribution. On that basis, 211At-3-Lu was selected and evaluated in cell uptake and internalization studies, and biodistribution and PSMA-expressing (PSMA+) PC3 PIP tumor growth control were evaluated in experimental flank and metastatic (PC3-ML-Luc) models. A long-term (13-mo) toxicity study was performed for 211At-3-Lu, including tissue chemistries and histopathology. Results: The radiochemical yield of 211At-3-Lu was 17.8% ± 8.2%. Lead compound 211At-3-Lu demonstrated total uptake within PSMA+ PC3 PIP cells of 13.4 ± 0.5% of the input dose after 4 h of incubation, with little uptake in control cells. In SCID mice, 211At-3-Lu provided uptake that was 30.6 ± 4.8 percentage injected dose per gram (%ID/g) in PSMA+ PC3 PIP tumor at 1 h after injection, and this uptake decreased to 9.46 ± 0.96 %ID/g by 24 h. Tumor-to-salivary gland and tumor-to-kidney ratios were 129 ± 99 at 4 h and 130 ± 113 at 24 h, respectively. Deastatination was not significant (stomach, 0.34 ± 0.20 %ID/g at 4 h). Dose-dependent survival was demonstrated at higher doses (>1.48 MBq) in both flank and metastatic models. There was little off-target toxicity, as demonstrated by hematopoietic stability, unchanged tissue chemistries, weight gain rather than loss throughout treatment, and favorable histopathologic findings. Conclusion: Compound 211At-3-Lu or close analogs may provide limited and acceptable toxicity while retaining efficacy in management of prostate cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mease RC, Kang CM, Kumar V, et al. An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy. J Nucl Med. 2021. PMID: 34088772. doi:10.2967/jnumed.121.262098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。